PharmVar GeneFocus:CYP4F2。

IF 6.3 2区 医学 Q1 PHARMACOLOGY & PHARMACY Clinical Pharmacology & Therapeutics Pub Date : 2024-08-13 DOI:10.1002/cpt.3405
Pablo Zubiaur, Cristina Rodríguez-Antona, Erin C. Boone, Ann K. Daly, Evangelia Eirini Tsermpini, Lubna Q. Khasawneh, Katrin Sangkuhl, Jorge Duconge, Mariana R. Botton, Jessica Savieo, Charity Nofziger, Michelle Whirl-Carrillo, Teri E. Klein, Andrea Gaedigk
{"title":"PharmVar GeneFocus:CYP4F2。","authors":"Pablo Zubiaur,&nbsp;Cristina Rodríguez-Antona,&nbsp;Erin C. Boone,&nbsp;Ann K. Daly,&nbsp;Evangelia Eirini Tsermpini,&nbsp;Lubna Q. Khasawneh,&nbsp;Katrin Sangkuhl,&nbsp;Jorge Duconge,&nbsp;Mariana R. Botton,&nbsp;Jessica Savieo,&nbsp;Charity Nofziger,&nbsp;Michelle Whirl-Carrillo,&nbsp;Teri E. Klein,&nbsp;Andrea Gaedigk","doi":"10.1002/cpt.3405","DOIUrl":null,"url":null,"abstract":"<p>The Pharmacogene Variation Consortium (PharmVar) serves as a global repository providing star (*) allele nomenclature for the polymorphic human <i>CYP4F2</i> gene. <i>CYP4F2</i> genetic variation impacts the metabolism of vitamin K, which is associated with warfarin dose requirements, and the metabolism of drugs, such as imatinib or fingolimod, and certain endogenous compounds including vitamin E and eicosanoids. This GeneFocus provides a comprehensive overview and summary of <i>CYP4F2</i> genetic variation including the characterization of 14 novel star alleles, <i>CYP4F2*4</i> through <i>*17</i>. A description of how haplotype information cataloged by PharmVar is utilized by the Pharmacogenomics Knowledgebase (PharmGKB) and the Clinical Pharmacogenetics Implementation Consortium (CPIC) is also provided.</p>","PeriodicalId":153,"journal":{"name":"Clinical Pharmacology & Therapeutics","volume":"116 4","pages":"963-975"},"PeriodicalIF":6.3000,"publicationDate":"2024-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cpt.3405","citationCount":"0","resultStr":"{\"title\":\"PharmVar GeneFocus: CYP4F2\",\"authors\":\"Pablo Zubiaur,&nbsp;Cristina Rodríguez-Antona,&nbsp;Erin C. Boone,&nbsp;Ann K. Daly,&nbsp;Evangelia Eirini Tsermpini,&nbsp;Lubna Q. Khasawneh,&nbsp;Katrin Sangkuhl,&nbsp;Jorge Duconge,&nbsp;Mariana R. Botton,&nbsp;Jessica Savieo,&nbsp;Charity Nofziger,&nbsp;Michelle Whirl-Carrillo,&nbsp;Teri E. Klein,&nbsp;Andrea Gaedigk\",\"doi\":\"10.1002/cpt.3405\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>The Pharmacogene Variation Consortium (PharmVar) serves as a global repository providing star (*) allele nomenclature for the polymorphic human <i>CYP4F2</i> gene. <i>CYP4F2</i> genetic variation impacts the metabolism of vitamin K, which is associated with warfarin dose requirements, and the metabolism of drugs, such as imatinib or fingolimod, and certain endogenous compounds including vitamin E and eicosanoids. This GeneFocus provides a comprehensive overview and summary of <i>CYP4F2</i> genetic variation including the characterization of 14 novel star alleles, <i>CYP4F2*4</i> through <i>*17</i>. A description of how haplotype information cataloged by PharmVar is utilized by the Pharmacogenomics Knowledgebase (PharmGKB) and the Clinical Pharmacogenetics Implementation Consortium (CPIC) is also provided.</p>\",\"PeriodicalId\":153,\"journal\":{\"name\":\"Clinical Pharmacology & Therapeutics\",\"volume\":\"116 4\",\"pages\":\"963-975\"},\"PeriodicalIF\":6.3000,\"publicationDate\":\"2024-08-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cpt.3405\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Pharmacology & Therapeutics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/cpt.3405\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Pharmacology & Therapeutics","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cpt.3405","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

药物基因变异联盟(PharmVar)是一个全球资料库,提供多态人类 CYP4F2 基因的星形(*)等位基因命名法。CYP4F2 基因变异会影响维生素 K 的代谢(这与华法林的剂量要求有关)以及药物(如伊马替尼或芬戈莫德)和某些内源性化合物(包括维生素 E 和二十酸)的代谢。本基因聚焦全面概述和总结了 CYP4F2 的遗传变异,包括 14 个新型星等位基因(CYP4F2*4 至 *17)的特征。此外,还介绍了药物基因组学知识库 (PharmGKB) 和临床药物基因组学实施联盟 (CPIC) 如何利用 PharmVar 编录的单倍型信息。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
PharmVar GeneFocus: CYP4F2

The Pharmacogene Variation Consortium (PharmVar) serves as a global repository providing star (*) allele nomenclature for the polymorphic human CYP4F2 gene. CYP4F2 genetic variation impacts the metabolism of vitamin K, which is associated with warfarin dose requirements, and the metabolism of drugs, such as imatinib or fingolimod, and certain endogenous compounds including vitamin E and eicosanoids. This GeneFocus provides a comprehensive overview and summary of CYP4F2 genetic variation including the characterization of 14 novel star alleles, CYP4F2*4 through *17. A description of how haplotype information cataloged by PharmVar is utilized by the Pharmacogenomics Knowledgebase (PharmGKB) and the Clinical Pharmacogenetics Implementation Consortium (CPIC) is also provided.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
12.70
自引率
7.50%
发文量
290
审稿时长
2 months
期刊介绍: Clinical Pharmacology & Therapeutics (CPT) is the authoritative cross-disciplinary journal in experimental and clinical medicine devoted to publishing advances in the nature, action, efficacy, and evaluation of therapeutics. CPT welcomes original Articles in the emerging areas of translational, predictive and personalized medicine; new therapeutic modalities including gene and cell therapies; pharmacogenomics, proteomics and metabolomics; bioinformation and applied systems biology complementing areas of pharmacokinetics and pharmacodynamics, human investigation and clinical trials, pharmacovigilence, pharmacoepidemiology, pharmacometrics, and population pharmacology.
期刊最新文献
Artificial Intelligence in European Medicines Regulation: From Vision to Action. Harnessing the Capabilities of Artificial Intelligence for the Benefit of Public and Animal Health. Mechanistic Modeling of Spatial Heterogeneity of Drug Penetration and Exposure in the Human Central Nervous System and Brain Tumors. Pharmacokinetic Modeling and Model-Based Hypothesis Generation for Dose Optimization of Clonidine in Neonates With Neonatal Opioid Withdrawal Syndrome. Planning and Implementing Master Protocol Trials in Japan: Key Considerations of the Japanese Guideline. Cerebral Ischemia Protection After Aneurysmal Subarachnoid Hemorrhage: CSF Nimodipine Levels After Intravenous Versus Oral Nimodipine Administration.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1